Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1–ALK fusion: a case report

被引:0
作者
Kazunori Honda
Shigenori Kadowaki
Kyoko Kato
Nobuhiro Hanai
Yasuhisa Hasegawa
Yasushi Yatabe
Kei Muro
机构
[1] Aichi Cancer Center Hospital,Department of Clinical Oncology
[2] Aichi Cancer Center Hospital,Department of Head and Neck Surgery
[3] Aichi Cancer Center Hospital,Department of Pathology and Molecular Diagnostics
来源
Investigational New Drugs | 2019年 / 37卷
关键词
Alectinib; Inflammatory myofibroblastic tumor; Head and neck; ALK gene rearrangement; SQSTM1-ALK gene fusion;
D O I
暂无
中图分类号
学科分类号
摘要
An inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal neoplasm that typically develops in the lungs and seldom in the head and neck region. It is often related to the anaplastic lymphoma kinase (ALK) fusion gene. Crizotinib, a first-generation ALK inhibitor, has been shown to have a notable response in patients with ALK-positive IMT. Here, we report the first case of a 46-year-old man with IMT harboring a novel SQSTM1–ALK fusion gene who demonstrated marked response to alectinib. The patient presented a right neck mass (5-cm diameter) that progressively enlarged and expanded to the upper mediastinum. ALK-rearranged IMT was diagnosed after complete tumor resection. Spindle cells displayed diffuse cytoplasmic staining for ALK on immunohistochemistry. A fluorescence in situ hybridization analysis revealed the translocation of a part of the ALK gene locus at chromosome 2p23. FoundationOne CDx™ assay identified an SQSTM1-ALK gene fusion. After a year, right cervical, subclavian, and mediastinal lymph node metastases, considered unresectable, developed. Notably, the patient exhibited a marked response to alectinib treatment and has sustained for 17 months following systemic therapy initiation without significant adverse events. This report highlights the possibility of alectinib being a reasonable option for advanced IMT with the SQSTM1-ALK fusion.
引用
收藏
页码:791 / 795
页数:4
相关论文
共 235 条
[1]  
Coffin CM(1995)Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases Am J Surg Pathol 19 859-872
[2]  
Watterson J(2002)Pulmonary inflammatory pseudotumor--a report of 28 cases Korean J Intern Med 17 252-258
[3]  
Priest JR(1994)Pulmonary plasma cell granuloma improves with corticosteroid therapy Chest 105 1574-1575
[4]  
Dehner LP(2006)Inflammatory myofibroblastic tumors J Surg Oncol 94 385-391
[5]  
Kim JH(2001)Alk1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor Mod Pathol 14 569-576
[6]  
Cho JH(2012)ALKoma: a cancer subtype with a shared target Cancer Discov 2 495-502
[7]  
Park MS(2014)Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions Cancer Discov 4 889-895
[8]  
Chung JH(2000)TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors Am J Pathol 157 377-384
[9]  
Lee JG(2010)Crizotinib in N Engl J Med 363 1727-1733
[10]  
Kim YS(2013)-rearranged inflammatory myofibroblastic tumor Lancet Oncol 14 472-480